572 related articles for article (PubMed ID: 22721490)
21. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose.
von Beckerath N; von Beckerath O; Koch W; Eichinger M; Schömig A; Kastrati A
Blood Coagul Fibrinolysis; 2005 Apr; 16(3):199-204. PubMed ID: 15795539
[TBL] [Abstract][Full Text] [Related]
22. Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients.
Bonello L; Bonello-Palot N; Armero S; Bonello C; Mokhtar OA; Arques S; Dignat-George F; Camoin-Jau L; Paganelli F
Thromb Res; 2010 Apr; 125(4):e167-70. PubMed ID: 19914687
[TBL] [Abstract][Full Text] [Related]
23. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
[TBL] [Abstract][Full Text] [Related]
24. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC
J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792
[TBL] [Abstract][Full Text] [Related]
25. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.
Campo G; Fileti L; de Cesare N; Meliga E; Furgieri A; Russo F; Colangelo S; Brugaletta S; Ferrari R; Valgimigli M;
J Am Coll Cardiol; 2010 Oct; 56(18):1447-55. PubMed ID: 20951320
[TBL] [Abstract][Full Text] [Related]
26. Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome.
Cuisset T; Hamilos M; Delrue M; Frère C; Verhamme K; Bartunek J; Saut N; Bonnet JL; Eijgelsheim M; Wijns W; Alessi MC; Barbato E
Thromb Haemost; 2010 Apr; 103(4):774-9. PubMed ID: 20135061
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults.
Sridharan K; Kataria R; Tolani D; Bendkhale S; Gogtay NJ; Thatte UM
Indian J Pharmacol; 2016; 48(4):350-354. PubMed ID: 27756942
[TBL] [Abstract][Full Text] [Related]
28. Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions.
Rudez G; Bouman HJ; van Werkum JW; Leebeek FW; Kruit A; Ruven HJ; ten Berg JM; de Maat MP; Hackeng CM
Circ Cardiovasc Genet; 2009 Oct; 2(5):515-21. PubMed ID: 20031628
[TBL] [Abstract][Full Text] [Related]
29. Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome.
Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Romero-Barra M; Camoin L; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
Thromb Haemost; 2007 Feb; 97(2):212-7. PubMed ID: 17264949
[TBL] [Abstract][Full Text] [Related]
30. Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response.
Cuisset T; Frere C; Quilici J; Morange PE; Camoin L; Bali L; Lambert M; Juhan-Vague I; Alessi MC; Bonnet JL
Thromb Res; 2009 Feb; 123(4):597-603. PubMed ID: 18499233
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement.
Müller I; Besta F; Schulz C; Massberg S; Schönig A; Gawaz M
Thromb Haemost; 2003 May; 89(5):783-7. PubMed ID: 12719773
[TBL] [Abstract][Full Text] [Related]
32. Increased mean platelet volume is associated with non-responsiveness to clopidogrel.
Asher E; Fefer P; Shechter M; Beigel R; Varon D; Shenkman B; Savion N; Hod H; Matetzky S
Thromb Haemost; 2014 Jul; 112(1):137-41. PubMed ID: 24696016
[TBL] [Abstract][Full Text] [Related]
33. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug.
Labarthe B; Théroux P; Angioï M; Ghitescu M
J Am Coll Cardiol; 2005 Aug; 46(4):638-45. PubMed ID: 16098428
[TBL] [Abstract][Full Text] [Related]
34. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44.
Frelinger AL; Michelson AD; Wiviott SD; Trenk D; Neumann FJ; Miller DL; Jakubowski JA; Costigan TM; McCabe CH; Antman EM; Braunwald E
Thromb Haemost; 2011 Aug; 106(2):219-26. PubMed ID: 21713327
[TBL] [Abstract][Full Text] [Related]
35. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
[TBL] [Abstract][Full Text] [Related]
36. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.
Aleil B; Jacquemin L; De Poli F; Zaehringer M; Collet JP; Montalescot G; Cazenave JP; Dickele MC; Monassier JP; Gachet C
JACC Cardiovasc Interv; 2008 Dec; 1(6):631-8. PubMed ID: 19463377
[TBL] [Abstract][Full Text] [Related]
37. Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
Tresukosol D; Suktitipat B; Hunnangkul S; Kamkaew R; Poldee S; Tassaneetrithep B; Likidlilid A
PLoS One; 2014; 9(10):e110188. PubMed ID: 25329996
[TBL] [Abstract][Full Text] [Related]
38. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
39. Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.
Stellbaum C; Ayral Y; Morguet A; Schultheiss HP; Rauch U
Cardiovasc Revasc Med; 2012; 13(3):159-66. PubMed ID: 22503564
[TBL] [Abstract][Full Text] [Related]
40. Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests.
Woo KS; Kim BR; Kim JE; Goh RY; Yu LH; Kim MH; Han JY
Korean J Lab Med; 2010 Oct; 30(5):460-8. PubMed ID: 20890076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
